MUTZ-6 and MUTZ-7 were derived independently, but from the same original peripheral blood cell sample as MUTZ-5. (PMID: 11516110)
253JB-V was derived from 253J following implantion into the muscular wall of the bladder of athymic nude mice. (10.1016/S0022-5347(01)66923-4).
NCI-BL1339 is a lymphoblastoid line from the same patient as NCI-H1339. (PMID: 8806092).
BE2-M17 is a subclone of SK-N-BE-2.;BE2-C is a subclone of SK-N-BE-2 (ATCC).
The L3-3 cell line is one of multiple lines established by sequential passages of a human pancreatic cancer cell line COLO-357 through the nude mouse liver. (PMID: 1544114)
WM983A & WM983B were both derived from the same patient. WM983A was derived from the original tumour and WM983B was derived from a metastatic site. (Rockland)
Lines LU-134-A and LU-134-B have been shown to be related (RIKEN).
CMK11-5 is a subclone of CMK (PMID: 1391807).;CMK, CMK-86 and CMK-11-5 share high SNP identity (DOI: 10.1038/nature11003).
451Lu is a selected xenograft aggressive metastatic sub-line of WM164 (Rockland).
COLO-201, COLO-205 and COLO-206F were all established from the ascites fluid of a patient with adenocarcinoma of the colon.;COLO-197 is a lymphoid line established from the original biopsy of the same patient.;COLO-200 is a lymphoid line establisted from the peripheral blood of the same patient (PMID: 565251).
GT3TKB has been shown to be cross contaminated with cell line RERF-LC-AI (PMID: 16643607).
SBC-1 and SBC-2 exhibit the same DNA profile (JCRB).
The human umbilical vein cell line, EA.hy926, was established by fusing primary human umbilical vein cells with a thioguanine-resistant clone of A549 by exposure to polyethylene glycol (PEG). Hybrid clones were selected in HAT medium and screened for factor VIII-related antigen. (ATCC)
EW-1 and EW-2 are from the same patient (PMID: 6713356).
HEC-1-A was derived from the same patient as HEC-1 (JCRB).;HEC-1-B is a substrain of HEC-1-A (ATCC).
HEL and HEL-92-1-7 share common ancestry (PMID: 25877200).
TGBC1TKB & TGBC2TKB are from the same patient (RIKEN).
HLE and HLF were derived from the same patient (PMID: 52570).
SK-MG-1 and Marcus share common ancestry (JCRB).;;RERF-LC-OK has been shown to be contaminated with Marcus cell line (ICLAC).
TE-2, TE-3, TE-7, TE-12 & TE-13 share common ancestry (PMID: 17804709)
SCLC-21H & SCLC-22H were derived from the same patient (DSMZ).
Ishikawa and Ishikawa(Heraklio)02ER- were derived from the same patient.
LN-464 and ACN share common ancestry (Sanger & Broad).
253JB-V was derived from 253J following implantion into the muscular wall of the bladder of athymic nude mice. (10.1016/S0022-5347(01)66923-4).
Hs-895-Sk is a normal cell line derived from the same patient as Hs-895-T (ATCC).
HCC1143-BL is a B-lymphoblastoid cell line initiated using peripheral blood lymphocytes obtained from the same patient as HCC1143 (ATCC).
YMB-1 and YMB-1-E have been shown to be derivatives of ZR-75-1 (JCRB, ICLAC, PMID: 23136038).
B239 and B240 are matched normal lines initiated by Epstein Barr virus (EBV) transformation of cells from the same blood sample as the tumour line NALM-19. (PMID: 1664237)
P2UR_K-562 is a P2U receptor-expressing subline derived from K-562 (RIKEN).
CGTH-W-1 is a subclone of SW-579 established in 1995 (PMID: 25877200).
COLO-201, COLO-205 and COLO-206F were all established from the ascites fluid of a patient with adenocarcinoma of the colon.;COLO-197 is a lymphoid line established from the original biopsy of the same patient.;COLO-200 is a lymphoid line establisted from the peripheral blood of the same patient (PMID: 565251).
MEC-1 and MEC-2 were both established from the same patient (PMID: 10071128).
KLM-1 and RPK-1 were both derived from the PK-1 cell line. ;KLM-1 was generated through injection of PK-1 and tumour formation in nude mice. (RIKEN, PMID: 8872523).;RPK-1 is a gemcitabine resistant sublcone of PK-1. (PMID: 22490663)
K029AX was derived from parental line K029. (Cellosaurus).
BE-13 and PEER show identical DNA fingerprints presumably due to cross-contamination; however, their diploid and tetraploid karyotypes are indicative of earlier and later passage numbers suggesting that BE-13 is derived from PEER, rather than vice-versa (DSMZ).
LC-1F (Floating variant) is from the same patient as LC-1-sq (Lung Cancer-1/Squamous). ;LC-1-sq-SF is a variant of LC-1-sq cultured in serum-free media (RIKEN).
RWPE-2 was derived from RWPE-1 by transformation with Ki-ras using the Kirsten murine sarcoma virus.;RWPE2-W99 cell line was derived from the RWPE-2 by cloning in soft agar to select cells that show high expression of Ki-ras (ATCC). ;WPE1-NA22 cells were derived from RWPE-1 cells by exposure to N-methyl-N-nitrosourea (ATCC).
MDA-MB-435 and its variant MDA-MB435S have been found to be cross contaminated with M14 (ICLAC, DOI: 10.1002/ijc.31067)
COLO-685 was established from the same patient as COLO-684 (DSMZ).
KPL-1 has been shown by DNA fingerprinting to be cross-contaminated with cell line MCF-7 (DSMZ).
WiDr has been shown to be a derivitive of HT-29 (ICLAC).
EW-1 and EW-2 are from the same patient (PMID: 6713356).
OC-314, OC-315 and OC-316 share common ancestry (PMID: 15677628). Sanger and Broad Institute genomic data supports this conclusion for OC-314 & OC-316 (no data has been generated for OC-315).
FTC-133, FTC-236 and FTC-238 were all derived from the same individual (ECACC).
PC-14 has been shown to be a derivitive of PC-9 (RIKEN, ECACC).
MMAc-SF is a serum-free medium adapted version of the MMAc cell line (RIKEN).
LC-1F (Floating variant) is from the same patient as LC-1-sq (Lung Cancer-1/Squamous). ;LC-1-sq-SF is a variant of LC-1-sq cultured in serum-free media (RIKEN).
TGBC1TKB & TGBC2TKB are from the same patient (RIKEN).
ETK-1 has been shown by STR profiling to be contaminated with SSP-25 (ICLAC)
ST is a subclone of Tanoue.;GR-ST is a subclone of ST cells transformed with human G-CSF receptor cDNA (JCRB).
Lines LU-134-A and LU-134-B have been shown to be related (RIKEN).
Malme-3M is a tumour line isolated from the same patient as Malme-3, a normal skin fibroblast (ATCC).
HUH-6-clone5 is a subclone of HuH-6 (PMID: 57894).
FTC-133, FTC-236 and FTC-238 were all derived from the same individual (ECACC).
MOLT-4 was derived from the same patient as MOLT-3 (ATCC).
HLE and HLF were derived from the same patient (PMID: 52570).
M120326_2 and M120327_3 were established from two different samples obtained from different regions of the same tumour.
MZ1-B is a transformed lymphoblastoid line derived from the same patient as MZ1-PC (Cellosaurus).
NCI-ADR-RES has been shown to be derivitive of OVCAR-8 (ICLAC)
COLO-775 has been shown to be a derivitive of RPMI-8226 (ICLAC).
UACC-62_CJ1 is a resistant sub-clone of UACC-62.
COLO-818 has been shown to come from the same patient as COLO-800 (DOI: 10.1002/ijc.25242.);COLO-800 and COLO-794 were both derived from the same patient (ECACC).
SNG-P and SNG-M were establised from primary and metastatic regions respectively of the same tumour (PMID: 858140).
MKN28 has been shown to be a derivitive of MKN74 (JCRB & ICLAC).
BB49-EBV is a matched normal line initiated by Epstein Barr virus (EBV) transformation from the same patient as BB49-HNC.
BB65-EBV is a matched normal line initiated by Epstein Barr virus (EBV) transformation from the same patient as BB65-RCC.
CP66-EBV is a matched normal line initiated by Epstein Barr virus (EBV) transformation from the same patient as CP66-MEL.
L542 is a matched normal line initiated by Epstein Barr virus (EBV) transformation from the same patient as D-542MG.
NCI-H125 and NCI-H513 have been show to be cross contaminated (ATCC, ICLAC)
WiDr has been shown to be a derivitive of HT-29 (ICLAC).
LB373-EBV is a matched normal line initiated by Epstein Barr virus (EBV) transformation from the same patient as LB373-MEL, the parental line of LB373-MEL-D.
LB771-PBL is a matched normal line initiated by Epstein Barr virus (EBV) transformation from the same patient as LB771-HNC.
LB996-EBV is a matched normal line initiated by Epstein Barr virus (EBV) transformation from the same patient as LB996-RCC.
ONCO-DG-1 is cross-contaminated with cell line OVCAR-3 (DSMZ).
B2-17 has been shown to be a derivitive of U251.;SNB19 has been shown to be a derivitive of U251 (ICLAC).
IHH-4 and TMH-1 share common ancestry having matching STR profiles (JCRB).
KNS-81-FD is derived from KNS-81 (JCRB).
SK-MG-1 and Marcus share common ancestry (JCRB).;;RERF-LC-OK has been shown to be contaminated with Marcus cell line (ICLAC).
SCC152 was established from a recurrence of a squamous cell carcinoma which had been used to derive SCC90 (ATCC).;
MOLT-16 and MOLT-17  are sister cell lines both established from the peripheral blood of the same patient (DSMZ).
MOLT-13 and MOLT-14 are simultaneous sister cell lines derived from the same patient (DSMZ).
BB30-PBL is a matched normal line initiated by Epstein Barr virus (EBV) transformation from the same patient as BB30-HNC.
CP50-EBV is a matched normal line initiated by Epstein Barr virus (EBV) transformation from the same patient as CP50-MEL-B.
ETK-1 has been shown by STR profiling to be contaminated with SSP-25 (ICLAC)
FTC-133, FTC-236 and FTC-238 were all derived from the same individual (ECACC).
CEM/C1 is a camptothecin resistant derivative of the human T cell leukemia cell line CCRF CEM.;CEM/C2 is a multi drug resistant derivative of the human T cell leukemia cell line CCRF CEM.;AGR-ON is a derivative of CEM-AG, itself a derivative of CCRF-CEM, selected for ability to produce CSF (ATCC).
HA7-EBV is a matched normal line initiated by Epstein Barr virus (EBV) transformation from the same patient as HA7-RCC.
LB2241-EBV is a matched normal line initiated by Epstein Barr virus (EBV) transformation from the same patient as LB2241-RCC.
LB2518-EBV is a matched normal line initiated by Epstein Barr virus (EBV) transformation from the same patient as LB2518-MEL.
LB647-PBL is a matched normal line initiated by Epstein Barr virus (EBV) transformation from the same patient as LB647-SCLC.
LB831-EBV is a matched normal line initiated by Epstein Barr virus (EBV) transformation from the same patient as LB831-BLC.
MKN28 has been shown to be a derivitive of MKN74 (JCRB & ICLAC).
PC-14 has been shown to be a derivitive of PC-9 (RIKEN, ECACC).
Hs-630-T has been shown to be a derivative of BeWo (PMID: 25877200, Cellosaurus).;;JEG-3 has the same DNA profile as BeWo; it was established by serial cloning of BeWo (ECACC & PMID: 4299001).
The ML-1, ML-2, and ML-3 lines were all established from the peripheral blood samples obtained from the same patient with acute myeloid leukemia (PMID: 3458526).
The ML-1, ML-2, and ML-3 lines were all established from the peripheral blood samples obtained from the same patient with acute myeloid leukemia (PMID: 3458526).
OPM-1 and OPM-2 were established from the peripheral blood of the same patient (PMID: 3926660).
GR-M has been shown to be cross-contaminated with PSN1 (DOI: 10.1038/nature14397).
PEO1 is from the same patient as the PEO4 and PEO6.;;PEO4 was collected after clinical resistance developed to chemotherapy.;PEO6 was collected at advanced, terminal stage disease. (ECACC)
PEO1 is from the same patient as the PEO4 and PEO6.;;PEO4 was collected after clinical resistance developed to chemotherapy.;PEO6 was collected at advanced, terminal stage disease. (ECACC)
LAMA-87 is a subclone of LAMA-84 obtained after subcutaneous transplantation of LAMA-84 cells into estrone-treated nude mice (DSMZ).
NCI-H1876 & NCI-H1882 & NCI-H1881 have been derived from the same same patient. (NCI-Navy Medical Oncology Brance Cell Line Supplement DOI: 10.1002/jcb.240630505)
GP5d has been established from the same adenocarcinoma as GP2d (ECACC).
LU-99A is a subclone of LU-99.
KP-3L cells were established using tumor nodules removed from the liver of mouse that had KP-3 cells injected into the spleen (JCRB).;KP-3N was derived from parent line KP-3 (PMID: 2172194).
KP-3L cells were established using tumor nodules removed from the liver of mouse that had KP-3 cells injected into the spleen (JCRB).;KP-3N was derived from parent line KP-3 (PMID: 2172194).
MY-M12 is the subclone of the MY (JCRB).
HEL and HEL-92-1-7 share common ancestry (PMID: 25877200).
HEC-1-A was derived from the same patient as HEC-1 (JCRB).;HEC-1-B is a substrain of HEC-1-A (ATCC).
RT112-84 and RT-112 share common ancestry (DSMZ, ECACC).
SBC-1 and SBC-2 exhibit the same DNA profile (JCRB).
SK-MG-1 and Marcus share common ancestry (JCRB).;;RERF-LC-OK has been shown to be contaminated with Marcus cell line (ICLAC).
KP-1N has been shown to be a derivative of PANC-1. ;KP-1NL is a subline of KP-1N (ICLAC).
MM1R is a dexamethasone resistant line derived from MM1. ;MM1S is a dexamethasone sensitive line derived from MM1 (ATCC).
SF767 has been shown to be a derivative of ME-180 (PMID: 22570425).
MC-CAR-Z2 is a derivative of MC-CAR (ATCC).
M059K and M059J cells concurrently from the same tumor specimen from a 33 year old male patient with untreated glioblastoma (ATCC).
NCI-H1870 and NCI-H1304 are known syonymous lines (ICLAC).
GR-M has been shown to be cross-contaminated with PSN1 (DOI: 10.1038/nature14397).
NCI-BL1395 is a lymphoblastoid line established from the same patient as NCI-H1395 (ATCC).
The ML-1, ML-2, and ML-3 lines were all established from the peripheral blood samples obtained from the same patient with acute myeloid leukemia (PMID: 3458526).
MUTZ-1 has been shown to be  derivative of NAMALWA (PMID: 19344951);NAMALWA-PNT is a subline of NAMALWA which shows differential expression of immunoglobulin and MYC genes and of some cell surface antigens (DSMZ).
OPM-1 and OPM-2 were established from the peripheral blood of the same patient (PMID: 3926660).
OVMIU and OVSAYO share common ancestry (JCRB).
PA-TU-8988T and PA-TU-8988S are sister cell lines established from the same patient (DSMZ, PMID:1348891).
PEO1 is from the same patient as the PEO4 and PEO6.;;PEO4 was collected after clinical resistance developed to chemotherapy.;PEO6 was collected at advanced, terminal stage disease. (ECACC)
1205Lu was dervied by serial passaging of WM793 through immune deficient mice and harvesting lung metastases (DOI: 10.4172/1948-5956.1000401).
WM115, WM266-4, WM239A and WM165-1 were all derived from the same patient. ;;WM115 cell line originated from the primary tumor, and WM239A, WM165-1 and WM266-4 were from individual lymph-node metastases (Rockland).
Hs-630-T has been shown to be a derivative of BeWo (PMID: 25877200, Cellosaurus).;;JEG-3 has the same DNA profile as BeWo; it was established by serial cloning of BeWo (ECACC & PMID: 4299001).
NCI-H1876 & NCI-H1882 & NCI-H1881 have been derived from the same same patient. (NCI-Navy Medical Oncology Brance Cell Line Supplement DOI: 10.1002/jcb.240630505)
DLD-1, HCT-15, HCT-8 and HRT-18 have been shown to have a common genetic origin (ECACC & PMID: 9809040).
DLD-1, HCT-15, HCT-8 and HRT-18 have been shown to have a common genetic origin (ECACC & PMID: 9809040).
COLO-818 has been shown to come from the same patient as COLO-800 (DOI: 10.1002/ijc.25242.);COLO-800 and COLO-794 were both derived from the same patient (ECACC).
COR-L23-R is a multi-drug resistant sub-line derived from the parent line COR-L23 after treatment with doxorubicin (ECACC).
NCI-BL2122 is a lymphoblastoid line from the same patient as NCI-H2122 (ATCC).
JURL-MK1 and JURL-MK2 are sister cell lines derived from the same patient (DSMZ).
Hs-294-T and A101D were isolated from the same donor tissue (ATCC).
451Lu is a selected xenograft aggressive metastatic sub-line of WM164 (Rockland).
HOS and 143B originated from the same patient: 143B is TK- and originated indirectly from HOS which is TK+ (ECACC & PMID: 20544518). ;HTK- and 143B have a common STR profile and are thought to be the same cell line (ECACC).
PLB-985 is known to be cross contaminated with HL-60 (ICLAC).
COLO-201, COLO-205 and COLO-206F were all established from the ascites fluid of a patient with adenocarcinoma of the colon.;COLO-197 is a lymphoid line established from the original biopsy of the same patient.;COLO-200 is a lymphoid line establisted from the peripheral blood of the same patient (PMID: 565251).
COLO-201, COLO-205 and COLO-206F were all established from the ascites fluid of a patient with adenocarcinoma of the colon.;COLO-197 is a lymphoid line established from the original biopsy of the same patient.;COLO-200 is a lymphoid line establisted from the peripheral blood of the same patient (PMID: 565251).
COLO-201, COLO-205 and COLO-206F were all established from the ascites fluid of a patient with adenocarcinoma of the colon.;COLO-197 is a lymphoid line established from the original biopsy of the same patient.;COLO-200 is a lymphoid line establisted from the peripheral blood of the same patient (PMID: 565251).
MEC-1 and MEC-2 were both established from the same patient (PMID: 10071128).
HP is a polytropic retroviral packaging cell line derived from the human fibrosarcoma cell line, HT-1080 (ATCC).;HX is a xenotropic retroviral packaging cell line derived from the human fibrosarcoma cell line, HT-1080 (ATCC).;PEAZ-1 has been shown to be contaminated wih HT-1080 (ICLAC).;
NCOL-1 has been shown to be derived from LoVo (ICLAC).
TDL-4 has been shown to be a derivative of Raji (ICLAC).;NC-37 has been shown to be a derivative of Raji by DNA fingerptrinting (ATCC).
The H9 cell line is a clonal derivative of the Hut 78 cell line (ATCC & PMID: 2567177).
SNP and STR profiling by the Sanger and Broad Institute indicate both EB-1 and EB2 share common ancestry.
HCC1428-BL is a B-lymphoblastoid cell line initiated by Epstein Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from the same patient as the breast carcinoma cell line HCC1428 (ATCC).
BE2-M17 is a subclone of SK-N-BE-2.;BE2-C is a subclone of SK-N-BE-2 (ATCC).
AU565 and SK-BR-3 were derived from the same patient (ATCC).
C3A is clonal derivative of Hep-G2 that was selected for strong contact inhibition of growth, high albumin production, high production of alpha fetoprotein (AFP) and ability to grow in glucose deficient medium (ATCC).
C-4-I and C-4-II were both derived from the same patient (ATCC).
HCMB and RPMI-7932 were both derived from the same patient (ATCC).;CHL-1 is a dervivative of RPMI-7932 (ATCC).;;COLO-699N (COLO-699) and COLO-738 were found to be indistinguishable from RPMI-7932 by STR profiling. All three cell lines were received from the same depositor (ECACC).
HCMB and RPMI-7932 were both derived from the same patient (ATCC).;CHL-1 is a dervivative of RPMI-7932 (ATCC).;;COLO-699N (COLO-699) and COLO-738 were found to be indistinguishable from RPMI-7932 by STR profiling. All three cell lines were received from the same depositor (ECACC).
NCI-H1993 and NCI-H2073 were derived from the same patient (ATCC).
IHH-4 and TMH-1 share common ancestry having matching STR profiles (JCRB).
CEM/C1 is a camptothecin resistant derivative of the human T cell leukemia cell line CCRF CEM.;CEM/C2 is a multi drug resistant derivative of the human T cell leukemia cell line CCRF CEM.;AGR-ON is a derivative of CEM-AG, itself a derivative of CCRF-CEM, selected for ability to produce CSF (ATCC).
KP-1N has been shown to be a derivative of PANC-1. ;KP-1NL is a subline of KP-1N (ICLAC).
KP-3L cells were established using tumor nodules removed from the liver of mouse that had KP-3 cells injected into the spleen (JCRB).;KP-3N was derived from parent line KP-3 (PMID: 2172194).
NCI-BL1770 is a lymphoblastoid line established from the same patient as NCI-H1770 (ATCC).
Panc-10-05 was derived from the same patient as the PL45 cell line (ATCC).
HCC1428-BL is a B-lymphoblastoid cell line initiated by Epstein Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from the same patient as the breast carcinoma cell line HCC1428 (ATCC).
HCC1954-BL is a B-lymphoblastoid cell line initiated from peripheral blood lymphocytes obtained from the same patient as HCC1954 (ATCC).
HCC38-BL is a B-lymphoblastoid cell line initiated by Epstein Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from the same patient as HCC38 (ATCC).
KCI-MOH1 is a derivative of HPAC (ICLAC).
LS1034-PBL is a matched normal line initiated by Epstein Barr virus (EBV) transformation from the same patient as LS1034.
M059K and M059J cells concurrently from the same tumor specimen from a 33 year old male patient with untreated glioblastoma (ATCC).
SF767 has been shown to be a derivative of ME-180 (PMID: 22570425).
MES-SA-MX2 is a mitoxantrone resistant derivative of the human uterine sarcoma cell line MES-SA (ATCC).;MES-SADx-5 is a multi drug-resistant subclone of MES-SA (ECACC).
NCI-BL128 is a matched normal line initiated by Epstein Barr virus (EBV) transformation from the same patient as NCI-H128. (ATCC)
NCI-H1870 and NCI-H1304 are known syonymous lines (ICLAC).
NCI-H1819 and the matched normal line NCI-BL1819 were derived from the same patient as NCI-H1693 following chemotherapy. (PMID: 8806092)
NCI-BL2141 is a lymphoblastoid line from the same patient as NCI-H2141 (ATCC).
COLO-829 was derived from a sample taken prior to chemotherapy for metastatic melanoma.;COLO 829BL was established from the same patient by Epstein Barr virus (EBV) transformation of a sample of peripheral blood (ATCC).
ACCS has been shown to be a derivitive of T24 (PMID: 20143388).;;SLR20 has been identified as a derivitive of T24 (ICLAC).
NCI-H1876 & NCI-H1882 & NCI-H1881 have been derived from the same same patient. (NCI-Navy Medical Oncology Brance Cell Line Supplement DOI: 10.1002/jcb.240630505)
KMS-12-PE and KMS-12-BM were both derived from the same patient (DSMZ).
EM-2 and EM-3 were derived from the same patient.;EM-2 was established +28 days after bone marrow transplantation.;EM-3 was established +47 days  after bone marrow transplantation (DSMZ).
MONO-MAC-1 and MONO-MAC-6 are simultaneous sister cell lines derived from a peripheral blood sample from the same patient (DSMZ).
RF-1 and RF-48 were derived from the same patient (PMID: 12226758)
EFM-192B and EFM-192C were established from the same patient as EFM-192A (DSMZ).
EFM-192B and EFM-192C were established from the same patient as EFM-192A (DSMZ).
WIL2-S is a HAT sensitive variant of the WIL2-NS cell line (ATCC).
Ramos-2G6-4C10 was derived from the Ramos cell line by repetitive cloning with selection for low constitutive expression of CD23 and maximum stimulation of CD23 expression by IL4 (ATCC).
NCI-BL1437 is a matched normal line initiated by Epstein Barr virus (EBV) transformation from the same patient as NCI-H1437. (ATCC)
CEM/C1 is a camptothecin resistant derivative of the human T cell leukemia cell line CCRF CEM.;CEM/C2 is a multi drug resistant derivative of the human T cell leukemia cell line CCRF CEM.;AGR-ON is a derivative of CEM-AG, itself a derivative of CCRF-CEM, selected for ability to produce CSF (ATCC).
HOS and 143B originated from the same patient: 143B is TK- and originated indirectly from HOS which is TK+ (ECACC & PMID: 20544518). ;HTK- and 143B have a common STR profile and are thought to be the same cell line (ECACC).
AZ-521 was originally reported as a human gastric cancer cell line. However, the STR DNA analysis pattern of AZ-521 is identical to the HuTu-80 cell line which was derived from a human duodenum carcinoma (JCRB).
J82-EBV was derived from the same patient as J82.
NCI-BL2087 is a lymphoblastoid line from the same patient as NCI-H2087 (ATCC).
NCI-BL209 is a lymphoblastoid line from the same patient as NCI-H209 (ATCC).
NCI-BL2171 is a lymphoblastoid line from the same patient as NCI-H2171 (ATCC).
NCI-BL2347 is a lymphoblastoid line from the same patient as NCI-H2347 (ATCC).
HeLaSF is a variant of Hela grown in serum free conditions. HEp-2 was originally thought to be derived from an epidermoid carcinoma of the larynx, but was found to contain HeLa marker chromosomes. DNA fingerprinting has confirmed it to have been established via HeLa cell contamination (ATCC).;BCG-823 was originally reported as a human gastric adenocarcinoma cell line. However, the STR DNA analysis pattern of BCG-823 showed contamination with the HeLa cell line (PMID: 26116706; 28851942).;GLC-82 was originally reported as a human lung adenocarcinoma cell line from a 32-year-old female patient. However, the STR DNA analysis pattern of GLC-82 showed contamination with the HeLa (PMID: 26116706).
HP is a polytropic retroviral packaging cell line derived from the human fibrosarcoma cell line, HT-1080 (ATCC).;HX is a xenotropic retroviral packaging cell line derived from the human fibrosarcoma cell line, HT-1080 (ATCC).;PEAZ-1 has been shown to be contaminated wih HT-1080 (ICLAC).;
NTERA-2 was established in 1980 from a nude mouse xenograft of the Tera 2 cell line. ;NTERA-2-cl-D1 is a sub-clone of NTERA-2 (ATCC).
NK-92MI is an interleukin 2 independent Natural Killer Cell line derived from the NK-92 by transfection (ATCC).
RERF-LC-MA has the same DNA profile as lung squamous carcinoma cell line SK-MES-1 (JCRB).
COLO-818 has been shown to come from the same patient as COLO-800 (DOI: 10.1002/ijc.25242.);COLO-800 and COLO-794 were both derived from the same patient (ECACC).
Hs-294-T and A101D were isolated from the same donor tissue (ATCC).
GA-10-Clone-4 and GA-10-Clone-20 are subclones of the GA 10 cell line derived by culturing the parental line on semi solid medium conditioned by a feeder layer (ATCC).
HCC1937-BL is a B-lymphoblastoid cell line initiated by Epstein Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from the same patient as HCC1937 (ATCC).
HCC1954-BL is a B-lymphoblastoid cell line initiated from peripheral blood lymphocytes obtained from the same patient as HCC1954 (ATCC).
HCC2157-BL is a B-lymphoblastoid cell line initiated by Epstein Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from the same patient as HCC2157 (ATCC).
HCC2218-BL is a B-lymphoblastoid cell line initiated by Epstein Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from the same patient as HCC2218 (ATCC).
PLB-985 is known to be cross contaminated with HL-60 (ICLAC).
HP is a polytropic retroviral packaging cell line derived from the human fibrosarcoma cell line, HT-1080 (ATCC).;HX is a xenotropic retroviral packaging cell line derived from the human fibrosarcoma cell line, HT-1080 (ATCC).;PEAZ-1 has been shown to be contaminated wih HT-1080 (ICLAC).;
NCI-BL2009 is a lymphoblastoid line derived from the same patient as NCI-H2009 (ATCC).
SW480 was derived from the primary adenocarcinoma of the colon.;;SW620 was derived the following year from a lymph node metastasis in the same patient (ATCC).
NCI-BL2126 is a B-lymphoblastoid cell line initiated by Epstein Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from the same patient as NCI-H2126 (ATCC).
HCC1599-BL is a B-lymphoblastoid cell line initiated by Epstein Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from the same patient as HCC1599 (ATCC).
U-118-MG and U-138-MG have identical VNTR, similar STR patterns and are very similar cytogenetically sharing at least six derivative marker chromosomes. (ATCC). ;1321N1 is a subclone of 1181N1 which itself is a subclone of U-118 MG  (ECACC).
LS-180 is a variant of LS-174T that has not been trypsinized during subculture, however LS-174T has been subcultured by trypsinization (ATCC).
RT112-84 and RT-112 share common ancestry (DSMZ, ECACC).
COR-L23-R is a multi-drug resistant sub-line derived from the parent line COR-L23 after treatment with doxorubicin (ECACC).
TDL-4 has been shown to be a derivative of Raji (ICLAC).;NC-37 has been shown to be a derivative of Raji by DNA fingerptrinting (ATCC).
The human umbilical vein cell line, EA.hy926, was established by fusing primary human umbilical vein cells with a thioguanine-resistant clone of A549 by exposure to polyethylene glycol (PEG). Hybrid clones were selected in HAT medium and screened for factor VIII-related antigen. (ATCC)
AU565 and SK-BR-3 were derived from the same patient (ATCC).
C-4-I and C-4-II were both derived from the same patient (ATCC).
HCMB and RPMI-7932 were both derived from the same patient (ATCC).;CHL-1 is a dervivative of RPMI-7932 (ATCC).;;COLO-699N (COLO-699) and COLO-738 were found to be indistinguishable from RPMI-7932 by STR profiling. All three cell lines were received from the same depositor (ECACC).
COLO-320 and COLO-320-HSR share common ancestry.
COLO-829 was derived from a sample taken prior to chemotherapy for metastatic melanoma.;COLO 829BL was established from the same patient by Epstein Barr virus (EBV) transformation of a sample of peripheral blood (ATCC).
HCC1187-BL is a B-lymphoblastoid cell line initiated by Epstein Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from the same patient as HCC1187 (ATCC).
Hey-A8 and Hey-C2, are Cisplatin resistant derivations of HEY generated in athymic nude mice (PMID: 23934194).
TDL-4 has been shown to be a derivative of Raji (ICLAC).;NC-37 has been shown to be a derivative of Raji by DNA fingerptrinting (ATCC).
IGR-37 and IGR-39 derived from the same patient.;IGR-37 was established from a lymph node metastasis.;IGR-39 was established from a primary (achromic) cutaneous tumor (DSMZ).
A2780cis is a cisplatin resistant subclone of A2780.;A2780ADR is an adriamycin resistant subclone of A2780 (ECACC).
A2780cis is a cisplatin resistant subclone of A2780.;A2780ADR is an adriamycin resistant subclone of A2780 (ECACC).
Hey-A8 and Hey-C2, are Cisplatin resistant derivations of HEY generated in athymic nude mice (PMID: 23934194).
J-RT3-T3-5 is a derivative mutant of the Jurkat subclone Jurkat-Clone-E61 that lacks the beta chain of the T cell antigen receptor (ATCC).;A3 is a wild-type A3 subclone of Jurkat generated through treatment with Fas Antibody and is very sensitive to Fas-mediated apoptosis (ATCC).;I-9-2 and I-2-1 are subclones of A3 generated by treating A3 clone with ICR-191 (frameshifting mutagen) in the presence of Fas Antibody for 3-5 weeks (ATCC).;I-9-2 has a mutation in the cysteine protease caspase-8/FLICE (ATCC).;I-2-1 has amutation in the adaptor FADD (ATCC).;Jurkat-Clone-E61 is a clone of Jurkat-FHCRC which is itself a derivative of the Jurkat cell line (ATCC).;JKT-beta-del is a derivative of Jurkat isolated by cell sorting and lacks the surface expression of the T-cell receptor alpha/beta/CD3 complex. (JCRB)
MDA-MB-435 and its variant MDA-MB435S have been found to be cross contaminated with M14 (ICLAC, DOI: 10.1002/ijc.31067)
J-RT3-T3-5 is a derivative mutant of the Jurkat subclone Jurkat-Clone-E61 that lacks the beta chain of the T cell antigen receptor (ATCC).;A3 is a wild-type A3 subclone of Jurkat generated through treatment with Fas Antibody and is very sensitive to Fas-mediated apoptosis (ATCC).;I-9-2 and I-2-1 are subclones of A3 generated by treating A3 clone with ICR-191 (frameshifting mutagen) in the presence of Fas Antibody for 3-5 weeks (ATCC).;I-9-2 has a mutation in the cysteine protease caspase-8/FLICE (ATCC).;I-2-1 has amutation in the adaptor FADD (ATCC).;Jurkat-Clone-E61 is a clone of Jurkat-FHCRC which is itself a derivative of the Jurkat cell line (ATCC).;JKT-beta-del is a derivative of Jurkat isolated by cell sorting and lacks the surface expression of the T-cell receptor alpha/beta/CD3 complex. (JCRB)
J-RT3-T3-5 is a derivative mutant of the Jurkat subclone Jurkat-Clone-E61 that lacks the beta chain of the T cell antigen receptor (ATCC).;A3 is a wild-type A3 subclone of Jurkat generated through treatment with Fas Antibody and is very sensitive to Fas-mediated apoptosis (ATCC).;I-9-2 and I-2-1 are subclones of A3 generated by treating A3 clone with ICR-191 (frameshifting mutagen) in the presence of Fas Antibody for 3-5 weeks (ATCC).;I-9-2 has a mutation in the cysteine protease caspase-8/FLICE (ATCC).;I-2-1 has amutation in the adaptor FADD (ATCC).;Jurkat-Clone-E61 is a clone of Jurkat-FHCRC which is itself a derivative of the Jurkat cell line (ATCC).;JKT-beta-del is a derivative of Jurkat isolated by cell sorting and lacks the surface expression of the T-cell receptor alpha/beta/CD3 complex. (JCRB)
MUTZ-1 has been shown to be  derivative of NAMALWA (PMID: 19344951);NAMALWA-PNT is a subline of NAMALWA which shows differential expression of immunoglobulin and MYC genes and of some cell surface antigens (DSMZ).
LAMA-87 is a subclone of LAMA-84 obtained after subcutaneous transplantation of LAMA-84 cells into estrone-treated nude mice (DSMZ).
BE2-M17 is a subclone of SK-N-BE-2.;BE2-C is a subclone of SK-N-BE-2 (ATCC).
HeLaSF is a variant of Hela grown in serum free conditions. HEp-2 was originally thought to be derived from an epidermoid carcinoma of the larynx, but was found to contain HeLa marker chromosomes. DNA fingerprinting has confirmed it to have been established via HeLa cell contamination (ATCC).;BCG-823 was originally reported as a human gastric adenocarcinoma cell line. However, the STR DNA analysis pattern of BCG-823 showed contamination with the HeLa cell line (PMID: 26116706; 28851942).;GLC-82 was originally reported as a human lung adenocarcinoma cell line from a 32-year-old female patient. However, the STR DNA analysis pattern of GLC-82 showed contamination with the HeLa (PMID: 26116706).
CMK11-5 is a subclone of CMK (PMID: 1391807).;CMK, CMK-86 and CMK-11-5 share high SNP identity (DOI: 10.1038/nature11003).
ST is a subclone of Tanoue.;GR-ST is a subclone of ST cells transformed with human G-CSF receptor cDNA (JCRB).
MES-SA-MX2 is a mitoxantrone resistant derivative of the human uterine sarcoma cell line MES-SA (ATCC).;MES-SADx-5 is a multi drug-resistant subclone of MES-SA (ECACC).
HEC-1-A was derived from the same patient as HEC-1 (JCRB).;HEC-1-B is a substrain of HEC-1-A (ATCC).
J-RT3-T3-5 is a derivative mutant of the Jurkat subclone Jurkat-Clone-E61 that lacks the beta chain of the T cell antigen receptor (ATCC).;A3 is a wild-type A3 subclone of Jurkat generated through treatment with Fas Antibody and is very sensitive to Fas-mediated apoptosis (ATCC).;I-9-2 and I-2-1 are subclones of A3 generated by treating A3 clone with ICR-191 (frameshifting mutagen) in the presence of Fas Antibody for 3-5 weeks (ATCC).;I-9-2 has a mutation in the cysteine protease caspase-8/FLICE (ATCC).;I-2-1 has amutation in the adaptor FADD (ATCC).;Jurkat-Clone-E61 is a clone of Jurkat-FHCRC which is itself a derivative of the Jurkat cell line (ATCC).;JKT-beta-del is a derivative of Jurkat isolated by cell sorting and lacks the surface expression of the T-cell receptor alpha/beta/CD3 complex. (JCRB)
CEM/C1 is a camptothecin resistant derivative of the human T cell leukemia cell line CCRF CEM.;CEM/C2 is a multi drug resistant derivative of the human T cell leukemia cell line CCRF CEM.;AGR-ON is a derivative of CEM-AG, itself a derivative of CCRF-CEM, selected for ability to produce CSF (ATCC).
GA-10-Clone-4 and GA-10-Clone-20 are subclones of the GA 10 cell line derived by culturing the parental line on semi solid medium conditioned by a feeder layer (ATCC).
RKO-E6 was generated from the colon carcinoma line RKO by transfection with pCMV E6 using Lipofectin (ATCC).
YMB-1 and YMB-1-E have been shown to be derivatives of ZR-75-1 (JCRB, ICLAC, PMID: 23136038).
P3HR-1 is a clonally derived subline of Jiyoye.;2B8 is a HAT sensitive fusion cell line derived from the P3HR-1 (ATCC).
MM1R is a dexamethasone resistant line derived from MM1. ;MM1S is a dexamethasone sensitive line derived from MM1 (ATCC).
IMR-5 is a subclone of IMR-32 (DOI: 10.1016/S0304-3835(02)00581-5).
TUR (TPA U937 Resistant) is a stably transfected cell line generated by Ralf Hass and Masanori Hirano in 1992 from U-937 (ATCC).
GA-10-Clone-4 and GA-10-Clone-20 are subclones of the GA 10 cell line derived by culturing the parental line on semi solid medium conditioned by a feeder layer (ATCC).
WM115, WM266-4, WM239A and WM165-1 were all derived from the same patient. ;;WM115 cell line originated from the primary tumor, and WM239A, WM165-1 and WM266-4 were from individual lymph-node metastases (Rockland).
1205Lu was dervied by serial passaging of WM793 through immune deficient mice and harvesting lung metastases (DOI: 10.4172/1948-5956.1000401).
GT3TKB has been shown to be cross contaminated with cell line RERF-LC-AI (PMID: 16643607).
RWPE-2 was derived from RWPE-1 by transformation with Ki-ras using the Kirsten murine sarcoma virus.;RWPE2-W99 cell line was derived from the RWPE-2 by cloning in soft agar to select cells that show high expression of Ki-ras (ATCC). ;WPE1-NA22 cells were derived from RWPE-1 cells by exposure to N-methyl-N-nitrosourea (ATCC).
PA-TU-8988T and PA-TU-8988S are sister cell lines established from the same patient (DSMZ, PMID:1348891).
LNZTA3WT4 was derived from the glioblastoma cell line LN-Z308 (ATCC).
HOS and 143B originated from the same patient: 143B is TK- and originated indirectly from HOS which is TK+ (ECACC & PMID: 20544518). ;HTK- and 143B have a common STR profile and are thought to be the same cell line (ECACC).
SW480 was derived from the primary adenocarcinoma of the colon.;;SW620 was derived the following year from a lymph node metastasis in the same patient (ATCC).
The C2BBe1 (brush border expressing) cell line was cloned in 1988 from the Caco 2 cell line (ATCC).
WM115, WM266-4, WM239A and WM165-1 were all derived from the same patient. ;;WM115 cell line originated from the primary tumor, and WM239A, WM165-1 and WM266-4 were from individual lymph-node metastases (Rockland).
Hey-A8 and Hey-C2, are Cisplatin resistant derivations of HEY generated in athymic nude mice (PMID: 23934194).
EM-2 and EM-3 were derived from the same patient.;EM-2 was established +28 days after bone marrow transplantation.;EM-3 was established +47 days  after bone marrow transplantation (DSMZ).
HCC-827-GR5 is a Gefitinib resistant clone of HCC-827. (10.1126/science.1141478).
IGR-37 and IGR-39 derived from the same patient.;IGR-37 was established from a lymph node metastasis.;IGR-39 was established from a primary (achromic) cutaneous tumor (DSMZ).
JURL-MK1 and JURL-MK2 are sister cell lines derived from the same patient (DSMZ).
KMS-12-PE and KMS-12-BM were both derived from the same patient (DSMZ).
SNU-C2A and SNU-C2B were both derived from the same nude mouse xenograft. SNU-C2A was derived at the third passage while SNU-C2B was derived at the fourth passage (ATCC).
RF-1 and RF-48 were derived from the same patient (PMID: 12226758)
RERF-LC-MA has the same DNA profile as lung squamous carcinoma cell line SK-MES-1 (JCRB).
SH-SY5Y is a thrice cloned (SK-N-SH -> SH-SY -> SH-SY5 -> SH-SY5Y) subline of the neuroblastoma cell line SK-N-SH (ATCC).
Hs-630-T has been shown to be a derivative of BeWo (PMID: 25877200, Cellosaurus).;;JEG-3 has the same DNA profile as BeWo; it was established by serial cloning of BeWo (ECACC & PMID: 4299001).
KNS-81-FD is derived from KNS-81 (JCRB).
LNZTA3WT4 was derived from the glioblastoma cell line LN-Z308 (ATCC).
MY-M12 is the subclone of the MY (JCRB).
NK-92MI is an interleukin 2 independent Natural Killer Cell line derived from the NK-92 by transfection (ATCC).
ACCS has been shown to be a derivitive of T24 (PMID: 20143388).;;SLR20 has been identified as a derivitive of T24 (ICLAC).
U-118-MG and U-138-MG have identical VNTR, similar STR patterns and are very similar cytogenetically sharing at least six derivative marker chromosomes. (ATCC). ;1321N1 is a subclone of 1181N1 which itself is a subclone of U-118 MG  (ECACC).
ICC10-6 and ICC10-8 were derived from the same individual (DepMap STR).
ICC10-6 and ICC10-8 were derived from the same individual (DepMap STR).
WM115, WM266-4, WM239A and WM165-1 were all derived from the same patient. ;;WM115 cell line originated from the primary tumor, and WM239A, WM165-1 and WM266-4 were from individual lymph-node metastases (Rockland).
J-RT3-T3-5 is a derivative mutant of the Jurkat subclone Jurkat-Clone-E61 that lacks the beta chain of the T cell antigen receptor (ATCC).;A3 is a wild-type A3 subclone of Jurkat generated through treatment with Fas Antibody and is very sensitive to Fas-mediated apoptosis (ATCC).;I-9-2 and I-2-1 are subclones of A3 generated by treating A3 clone with ICR-191 (frameshifting mutagen) in the presence of Fas Antibody for 3-5 weeks (ATCC).;I-9-2 has a mutation in the cysteine protease caspase-8/FLICE (ATCC).;I-2-1 has amutation in the adaptor FADD (ATCC).;Jurkat-Clone-E61 is a clone of Jurkat-FHCRC which is itself a derivative of the Jurkat cell line (ATCC).;JKT-beta-del is a derivative of Jurkat isolated by cell sorting and lacks the surface expression of the T-cell receptor alpha/beta/CD3 complex. (JCRB)
HCMB and RPMI-7932 were both derived from the same patient (ATCC).;CHL-1 is a dervivative of RPMI-7932 (ATCC).;;COLO-699N (COLO-699) and COLO-738 were found to be indistinguishable from RPMI-7932 by STR profiling. All three cell lines were received from the same depositor (ECACC).
MES-SA-MX2 is a mitoxantrone resistant derivative of the human uterine sarcoma cell line MES-SA (ATCC).;MES-SADx-5 is a multi drug-resistant subclone of MES-SA (ECACC).
OVMIU and OVSAYO share common ancestry (JCRB).
PK-45H and PK-45P were both derived from the same patient. (RIKEN).
SCLC-21H & SCLC-22H were derived from the same patient (DSMZ).
TE-2, TE-3, TE-7, TE-12 & TE-13 share common ancestry (PMID: 17804709)
RH-28 and RH-3 were both derived from the same tumour. (PMID: 9530337).
SCMC-RM2-1 is a sub-clone of SCMC-RM2. (PMID: 23882450).
MCC14-1 & MCC14-2 were both established from the same nodal metastasis. (PMID: 7814141).
LN-443 is a subline of LN-444, and accordingly, both lines contain the same PTEN mutation. (PubMed=22570425).
LN-319 was found to be a derivative of LN-992. (PubMed=22570425).
MOR/CPR has been developed by growing the parent line, MOR, in increasing concentrations of cisplatin. (ECACC),
WM983A & WM983B were both derived from the same patient. WM983A was derived from the original tumour and WM983B was derived from a metastatic site. (Rockland)
RH-28 and RH-3 were both derived from the same tumour. (PMID: 9530337).
RH-41 and RH-4 were both derived from the same patient sample. (PMID: 23882450)
MCC14-1 & MCC14-2 were both established from the same nodal metastasis. (PMID: 7814141).
MAC-1, MAC-2A & MAC-2B were all derived from the same patient. (10.1056/NEJM199204233261704).;Mac-1 was derived in 1985 from circulating Sézary-like cells in the peripheral blood.;Mac-2A and Mac-2B were started from separate skin-tumor nodules in 1987.
MAC-1, MAC-2A & MAC-2B were all derived from the same patient. (10.1056/NEJM199204233261704).;Mac-1 was derived in 1985 from circulating Sézary-like cells in the peripheral blood.;Mac-2A and Mac-2B were started from separate skin-tumor nodules in 1987.
LN-443 is a subline of LN-444, and accordingly, both lines contain the same PTEN mutation. (PubMed=22570425).
COV413A and COV413B are derived from the same patient. (ECACC).
PEO14, PEO23 and TO14 were derived from the same patient. (PMID: 3167863).;PEO14 and PEO23 samples were obtained from ascites, PEO14 prior to therapy and PEO23 following chemotherapy.;TO14 was derived from a solid metastasis in the omentum.
PEA1 and PEA2 were both derived from the same patient. PEA1 was obtained prior to therapy, PEA2 was obtained after chemotherapy. (PMID: 3167863)
CI formerly thought of as a B-lymphoblastoid sister of CII is now deemed a subclone of CII. (DSMZ)
PK-45H and PK-45P were both derived from the same patient. (RIKEN).
ACCS has been shown to be a derivitive of T24 (PMID: 20143388).;;SLR20 has been identified as a derivitive of T24 (ICLAC).
D-425MED and D-458MED are derived from the same patient. (PubMed=1822845).
PEO14, PEO23 and TO14 were derived from the same patient. (PMID: 3167863).;PEO14 and PEO23 samples were obtained from ascites, PEO14 prior to therapy and PEO23 following chemotherapy.;TO14 was derived from a solid metastasis in the omentum.
PEO14, PEO23 and TO14 were derived from the same patient. (PMID: 3167863).;PEO14 and PEO23 samples were obtained from ascites, PEO14 prior to therapy and PEO23 following chemotherapy.;TO14 was derived from a solid metastasis in the omentum.
PEA1 and PEA2 were both derived from the same patient. PEA1 was obtained prior to therapy, PEA2 was obtained after chemotherapy. (PMID: 3167863)
COG-AR-359 and COG-AR-382 are derived from the same patient. (http://cancerres.aacrjournals.org/content/68/9_Supplement/3743).
DERL-2 and DERL-7 are derived from the same patient. (DSMZ).
UACC-62_CJ1 is a resistant sub-clone of UACC-62.
COV413A and COV413B are derived from the same patient. (ECACC).
COV362-4 is a subline of an early passage of the cell line COV362. (ECACC).
COG-AR-359 and COG-AR-382 are derived from the same patient. (http://cancerres.aacrjournals.org/content/68/9_Supplement/3743).
COLO-685 was established from the same patient as COLO-684 (DSMZ).
LB1047-EBV is a matched normal line initiated by Epstein Barr virus (EBV) transformation from the same patient as LB1047-RCC.
MOLT-4 was derived from the same patient as MOLT-3 (ATCC).
D-425MED and D-458MED are derived from the same patient. (PubMed=1822845).
DERL-2 and DERL-7 are derived from the same patient. (DSMZ).
CHLA-15 and CHLA-20 are derived from the same patient. (https://www.cccells.org/dl/NB_Data_Sheets/CHLA-20_Cell_Line_Data_Sheet_COGcell_org.pdf).
CHLA-9 and CHLA-10 were derived from the same patient. (10.1158/0008-5472.CAN-04-0377).
CHLA-15 and CHLA-20 are derived from the same patient. (https://www.cccells.org/dl/NB_Data_Sheets/CHLA-20_Cell_Line_Data_Sheet_COGcell_org.pdf).
CHLA-9 and CHLA-10 were derived from the same patient. (10.1158/0008-5472.CAN-04-0377).
MAC-1, MAC-2A & MAC-2B were all derived from the same patient. (10.1056/NEJM199204233261704).;Mac-1 was derived in 1985 from circulating Sézary-like cells in the peripheral blood.;Mac-2A and Mac-2B were started from separate skin-tumor nodules in 1987.
SEM-K2 is subclone of the SEM cell line (DOI: 10.1111/j.1365-2141.1995.tb05207.x)
LC-1F (Floating variant) is from the same patient as LC-1-sq (Lung Cancer-1/Squamous). ;LC-1-sq-SF is a variant of LC-1-sq cultured in serum-free media (RIKEN).
F-36P is the parent of F-36E.  F-36P has been cultured with granulocyte-macrophage colony-stimulating factor (GM-CSF) or interleukin-3 (IL-3) while F-36E can be maintained in the presence of erythropoietin only. (PubMed=1834251).
Hs-688A-T was derived from the primary tumour and Hs-688B-T was derived from a lymph node metastasis in the same patient. (ATCC).
Hs-688A-T was derived from the primary tumour and Hs-688B-T was derived from a lymph node metastasis in the same patient. (ATCC).
K029AX was derived from parental line K029. (Cellosaurus).
F-36P is the parent of F-36E.  F-36P has been cultured with granulocyte-macrophage colony-stimulating factor (GM-CSF) or interleukin-3 (IL-3) while F-36E can be maintained in the presence of erythropoietin only. (PubMed=1834251).
SCC152 was established from a recurrence of a squamous cell carcinoma which had been used to derive SCC90 (ATCC).;
MUTZ-6 and MUTZ-7 were derived independently, but from the same original peripheral blood cell sample as MUTZ-5. (PMID: 11516110)
SEM-K2 is subclone of the SEM cell line (DOI: 10.1111/j.1365-2141.1995.tb05207.x)
CI formerly thought of as a B-lymphoblastoid sister of CII is now deemed a subclone of CII. (DSMZ)
KLM-1 and RPK-1 were both derived from the PK-1 cell line. ;KLM-1 was generated through injection of PK-1 and tumour formation in nude mice. (RIKEN, PMID: 8872523).;RPK-1 is a gemcitabine resistant sublcone of PK-1. (PMID: 22490663)
LN-319 was found to be a derivative of LN-992. (PubMed=22570425).
COV362-4 is a subline of an early passage of the cell line COV362. (ECACC).
KLM-1 and RPK-1 were both derived from the PK-1 cell line. ;KLM-1 was generated through injection of PK-1 and tumour formation in nude mice. (RIKEN, PMID: 8872523).;RPK-1 is a gemcitabine resistant sublcone of PK-1. (PMID: 22490663)
SCMC-RM2-1 is a sub-clone of SCMC-RM2. (PMID: 23882450).
HCC-827-GR5 is a Gefitinib resistant clone of HCC-827. (10.1126/science.1141478).
U-343-MG and U-343-MGa were both derived from the same patient biopsy (PMID: 3497714). GOS-3 is a derivative of the human glioblastoma cell line U-343-MG. (DSMZ).
U-343-MG and U-343-MGa were both derived from the same patient biopsy (PMID: 3497714). GOS-3 is a derivative of the human glioblastoma cell line U-343-MG. (DSMZ).
The L3-3 cell line is one of multiple lines established by sequential passages of a human pancreatic cancer cell line COLO-357 through the nude mouse liver. (PMID: 1544114)
KMS-28-PE and KMS-28-BM were both derived independent samples, pleural effusion and bone marrow, from the same patient (PMID: 11886382).
MDA-PCa-2a and MDA-PCa-2b were derived from samples taken from different areas of the same tumour resection. (PMID: 9815652)
NCI-BL2077 is a matched normal line initiated by Epstein Barr virus (EBV) transformation from the same patient as NCI-H2077. (PMID: 8806092)
NCI-H1819 and the matched normal line NCI-BL1819 were derived from the same patient as NCI-H1693 following chemotherapy. (PMID: 8806092)
U-343-MG and U-343-MGa were both derived from the same patient biopsy (PMID: 3497714). GOS-3 is a derivative of the human glioblastoma cell line U-343-MG. (DSMZ).
COLO-775 has been shown to be a derivitive of RPMI-8226 (ICLAC).
KMS-28-PE and KMS-28-BM were both derived independent samples, pleural effusion and bone marrow, from the same patient (PMID: 11886382).
NCI-BL2077 is a matched normal line initiated by Epstein Barr virus (EBV) transformation from the same patient as NCI-H2077. (PMID: 8806092)
MUTZ-6 and MUTZ-7 were derived independently, but from the same original peripheral blood cell sample as MUTZ-5. (PMID: 11516110)
ONCO-DG-1 is cross-contaminated with cell line OVCAR-3 (DSMZ).
MOR/CPR has been developed by growing the parent line, MOR, in increasing concentrations of cisplatin. (ECACC),
MDA-PCa-2a and MDA-PCa-2b were derived from samples taken from different areas of the same tumour resection. (PMID: 9815652)
MOLT-13 and MOLT-14 are simultaneous sister cell lines derived from the same patient (DSMZ).
MOLT-16 and MOLT-17  are sister cell lines both established from the peripheral blood of the same patient (DSMZ).
SNG-P and SNG-M were establised from primary and metastatic regions respectively of the same tumour (PMID: 858140).
LB771-PBL is a matched normal line initiated by Epstein Barr virus (EBV) transformation from the same patient as LB771-HNC.
Hs-934-T and HS-935-T were both derived from the same patient (Cellosaurus).
Hs-888-Lu and Hs-888-Sk were derived using normal tissue from the same patient as the metastatically derived tumour cell line Hs-888-T (ATCC).
Hs-870-T, Hs-860-T and Hs-791-T were derived from the same patient (Cellosaurus, ATCC)
HuG1-N and HuG1-PI were derived from the parental line HuG1 (JCRB).
Hs-934-T and HS-935-T were both derived from the same patient (Cellosaurus).
Hs-895-Sk is a normal cell line derived from the same patient as Hs-895-T (ATCC).
Hs-888-Lu and Hs-888-Sk were derived using normal tissue from the same patient as the metastatically derived tumour cell line Hs-888-T (ATCC).
Hs-870-T, Hs-860-T and Hs-791-T were derived from the same patient (Cellosaurus, ATCC)
LB373-EBV is a matched normal line initiated by Epstein Barr virus (EBV) transformation from the same patient as LB373-MEL, the parental line of LB373-MEL-D.
HuG1-N and HuG1-PI were derived from the parental line HuG1 (JCRB).
KP-1N has been shown to be a derivative of PANC-1. ;KP-1NL is a subline of KP-1N (ICLAC).
Hs-888-Lu and Hs-888-Sk were derived using normal tissue from the same patient as the metastatically derived tumour cell line Hs-888-T (ATCC).
LS-180 is a variant of LS-174T that has not been trypsinized during subculture, however LS-174T has been subcultured by trypsinization (ATCC).
Hs-870-T, Hs-860-T and Hs-791-T were derived from the same patient (Cellosaurus, ATCC)
GP5d has been established from the same adenocarcinoma as GP2d (ECACC).
CP66-EBV is a matched normal line initiated by Epstein Barr virus (EBV) transformation from the same patient as CP66-MEL.
DLD-1, HCT-15, HCT-8 and HRT-18 have been shown to have a common genetic origin (ECACC & PMID: 9809040).
SNU-C2A and SNU-C2B were both derived from the same nude mouse xenograft. SNU-C2A was derived at the third passage while SNU-C2B was derived at the fourth passage (ATCC).
YSCCC-G10 and YSCCC-G100 are gemcitabine‐resistant cells generated by exposing the YSCCC cell line to 10nM and 100nM of gemcitabine respectively (DOI: 10.1007/s00534-011-0376-7).
VP229 was derived from a breast cancer biopsy obtained from the primary tumour, VP267 was derived 14 months later from a local recurrence of the tumour (ECACC).
UPCI-SCC-026 was derived following recurrance from the same patient as UPCI-SCC-016 (DOI: 10.1016/j.oraloncology.2007.05.003).
SKG-IIB was established from the same individual as SKG-II (https://ci.nii.ac.jp/naid/110002117678/en).;The SKG-II-LUC and SKG-II-S cell lines were derived from SKG-II by transfection with LUC or TS-expressing vectors respectively (DOI: 10.1159/000063804). ;SKG-II-SF was established from SKG-II by growth in serum-free media (PMID: 9573483). ;The HKMUS cell line has been shown to be a SKG-II-SF derivative (PMID: 20143388).
MUTZ-1 has been shown to be  derivative of NAMALWA (PMID: 19344951);NAMALWA-PNT is a subline of NAMALWA which shows differential expression of immunoglobulin and MYC genes and of some cell surface antigens (DSMZ).
HCC1395-BL is a B-lymphoblastoid cell line initiated by Epstein Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from the same patient as the breast carcinoma cell line HCC1395 (ATCC).
OC-314, OC-315 and OC-316 share common ancestry (PMID: 15677628). Sanger and Broad Institute genomic data supports this conclusion for OC-314 & OC-316 (no data has been generated for OC-315).
VP229 was derived from a breast cancer biopsy obtained from the primary tumour, VP267 was derived 14 months later from a local recurrence of the tumour (ECACC).
UPCI-SCC-026 was derived following recurrance from the same patient as UPCI-SCC-016 (DOI: 10.1016/j.oraloncology.2007.05.003).
U-HO1-PTPN1 was derived from U-HO1 by stable transfection with non-receptor protein-tyrosine phosphatase N1 (PTPN1) (DOI: 10.1186/1471-2121-11-99).
OMM2-5, OMM2-3 and Mel-270 are derived from the same patient (PMID: 28018010).
OMM2-5, OMM2-3 and Mel-270 are derived from the same patient (PMID: 28018010).
RCC4-emptyvector and RCC4-VHL were derived from the RCC4 cell line by stable transfection with pcDNA3 and pCDNA3-VHL respectively (ECACC). ;SLR24 was shown to be a RCC4 derivative (ICLAC).
The SKG-I-TS cell line was derived from SKG-I by transfection with a thymidylate synthase (TS)-expressing vector (DOI: 10.1002/ijc.11221).
OMM2-5, OMM2-3 and Mel-270 are derived from the same patient (PMID: 28018010).
SKG-IIB was established from the same individual as SKG-II (https://ci.nii.ac.jp/naid/110002117678/en).;The SKG-II-LUC and SKG-II-S cell lines were derived from SKG-II by transfection with LUC or TS-expressing vectors respectively (DOI: 10.1159/000063804). ;SKG-II-SF was established from SKG-II by growth in serum-free media (PMID: 9573483). ;The HKMUS cell line has been shown to be a SKG-II-SF derivative (PMID: 20143388).
SNP and STR profiling by the Sanger and Broad Institute indicate both EB-1 and EB2 share common ancestry.
P3HR-1 is a clonally derived subline of Jiyoye.;2B8 is a HAT sensitive fusion cell line derived from the P3HR-1 (ATCC).
NCOL-1 has been shown to be derived from LoVo (ICLAC).
MZ7-B and MZ7-mel are derived from the same patient (DOI: 10.1073/pnas.0500090102).
94T778 was established from the second recurrence of the tumor from the same patient from which the 93T449 cell line was derived (ATCC).
Onda-9R was established from a recurrence of a glioblastoma which had previously been sampled and used to derive Onda-9. ;Onda-9R-B12 is a clonal cell line derived from Onda-9R (JCRB).
TIG-3 and TIG-3S were established from fetal lung and skin samples respectively from the same individual (DOI: 10.34425/zs000693).;TIG-3TD is a TERT-immortalised cell line of TIG-3 (Cellosaurus).
Mero-48a (Pleural Cavity), Mero-48b (Omentum), Mero-48c (Liver) and Mero-48d (Pericardium) are derived from 4 solid tumours taken from the same patient (DOI: 10.1002/ijc.2910440212).
Mero-48a (Pleural Cavity), Mero-48b (Omentum), Mero-48c (Liver) and Mero-48d (Pericardium) are derived from 4 solid tumours taken from the same patient (DOI: 10.1002/ijc.2910440212).
94T778 was established from the second recurrence of the tumor from the same patient from which the 93T449 cell line was derived (ATCC).
21NT and 21PT were independent samples derived from primary tumours from the same patient.;21MT was derived from a pleural effusion sample taken 1 year after the primary tumour samples and was subsequently used to establish the cell lines 21MT-1 and 21MT-2 (PMID: 1977518). ;H16N2 was derived from normal mammary epithelial cells taken from the same patient as the 21T series cell lines (DOI: 10.1186/s13058-019-1173-5).
21NT and 21PT were independent samples derived from primary tumours from the same patient.;21MT was derived from a pleural effusion sample taken 1 year after the primary tumour samples and was subsequently used to establish the cell lines 21MT-1 and 21MT-2 (PMID: 1977518). ;H16N2 was derived from normal mammary epithelial cells taken from the same patient as the 21T series cell lines (DOI: 10.1186/s13058-019-1173-5).
UT-7-EPO is an erythropoietin-dependent subline of UT-7 (DOI: 10.1182/blood.V82.2.456.456). ;UT-7-GM is a subline of UT-7 and is a bipotential cell line that can be induced to differentiate into erythroid and megakaryocytic lineages by EPO and TPO (DOI: 10.1182/blood.V89.11.4021). ;UT-7-TPO is a thrombopoietin-dependent subline of UT-7-GM (DOI: 10.1182/blood.V87.11.4552.bloodjournal87114552).
21NT and 21PT were independent samples derived from primary tumours from the same patient.;21MT was derived from a pleural effusion sample taken 1 year after the primary tumour samples and was subsequently used to establish the cell lines 21MT-1 and 21MT-2 (PMID: 1977518). ;H16N2 was derived from normal mammary epithelial cells taken from the same patient as the 21T series cell lines (DOI: 10.1186/s13058-019-1173-5).
SKG-IIB was established from the same individual as SKG-II (https://ci.nii.ac.jp/naid/110002117678/en).;The SKG-II-LUC and SKG-II-S cell lines were derived from SKG-II by transfection with LUC or TS-expressing vectors respectively (DOI: 10.1159/000063804). ;SKG-II-SF was established from SKG-II by growth in serum-free media (PMID: 9573483). ;The HKMUS cell line has been shown to be a SKG-II-SF derivative (PMID: 20143388).
RMZ-RC2 and RMZ-RC5 are clonal cell lines derived from RMZ (DOI: 10.1038/bjc.1986.273).
The SKG-I-TS cell line was derived from SKG-I by transfection with a thymidylate synthase (TS)-expressing vector (DOI: 10.1002/ijc.11221).
RCC4-emptyvector and RCC4-VHL were derived from the RCC4 cell line by stable transfection with pcDNA3 and pCDNA3-VHL respectively (ECACC). ;SLR24 was shown to be a RCC4 derivative (ICLAC).
Onda-9R was established from a recurrence of a glioblastoma which had previously been sampled and used to derive Onda-9. ;Onda-9R-B12 is a clonal cell line derived from Onda-9R (JCRB).
UT-7-EPO is an erythropoietin-dependent subline of UT-7 (DOI: 10.1182/blood.V82.2.456.456). ;UT-7-GM is a subline of UT-7 and is a bipotential cell line that can be induced to differentiate into erythroid and megakaryocytic lineages by EPO and TPO (DOI: 10.1182/blood.V89.11.4021). ;UT-7-TPO is a thrombopoietin-dependent subline of UT-7-GM (DOI: 10.1182/blood.V87.11.4552.bloodjournal87114552).
YSCCC-G10 and YSCCC-G100 are gemcitabine‐resistant cells generated by exposing the YSCCC cell line to 10nM and 100nM of gemcitabine respectively (DOI: 10.1007/s00534-011-0376-7).
SKG-IIB was established from the same individual as SKG-II (https://ci.nii.ac.jp/naid/110002117678/en).;The SKG-II-LUC and SKG-II-S cell lines were derived from SKG-II by transfection with LUC or TS-expressing vectors respectively (DOI: 10.1159/000063804). ;SKG-II-SF was established from SKG-II by growth in serum-free media (PMID: 9573483). ;The HKMUS cell line has been shown to be a SKG-II-SF derivative (PMID: 20143388).
AZ-521 was originally reported as a human gastric cancer cell line. However, the STR DNA analysis pattern of AZ-521 is identical to the HuTu-80 cell line which was derived from a human duodenum carcinoma (JCRB).
PG-B95-8 is a matched normal line initiated by Epstein Barr virus (EBV) transformation from the same patient as PGA-1 (DSMZ).
Mero-48a (Pleural Cavity), Mero-48b (Omentum), Mero-48c (Liver) and Mero-48d (Pericardium) are derived from 4 solid tumours taken from the same patient (DOI: 10.1002/ijc.2910440212).
RMZ-RC2 and RMZ-RC5 are clonal cell lines derived from RMZ (DOI: 10.1038/bjc.1986.273).
Onda-9R was established from a recurrence of a glioblastoma which had previously been sampled and used to derive Onda-9. ;Onda-9R-B12 is a clonal cell line derived from Onda-9R (JCRB).
OCI-Ly13-1 and OCI-Ly13-2 were derived from the same patient. ;OCI-Ly13-1 was established from a sample taken at diagnosis whereas OCI-Ly13-2 was established from a sample obtained during relapse (DOI: 10.1182/blood.V69.5.1307.1307).
OCI-Ly13-1 and OCI-Ly13-2 were derived from the same patient. ;OCI-Ly13-1 was established from a sample taken at diagnosis whereas OCI-Ly13-2 was established from a sample obtained during relapse (DOI: 10.1182/blood.V69.5.1307.1307).
MZ1-B is a transformed lymphoblastoid line derived from the same patient as MZ1-PC (Cellosaurus).
The hTERT-immortalized foreskin fibroblast cell line, BJ-5ta, was derived by transfecting the BJ foreskin fibroblast cell line with the pGRN145 hTERT-expressing plasmid (ATCC).
Mero-48a (Pleural Cavity), Mero-48b (Omentum), Mero-48c (Liver) and Mero-48d (Pericardium) are derived from 4 solid tumours taken from the same patient (DOI: 10.1002/ijc.2910440212).
TIG-3 and TIG-3S were established from fetal lung and skin samples respectively from the same individual (DOI: 10.34425/zs000693).;TIG-3TD is a TERT-immortalised cell line of TIG-3 (Cellosaurus).
21NT and 21PT were independent samples derived from primary tumours from the same patient.;21MT was derived from a pleural effusion sample taken 1 year after the primary tumour samples and was subsequently used to establish the cell lines 21MT-1 and 21MT-2 (PMID: 1977518). ;H16N2 was derived from normal mammary epithelial cells taken from the same patient as the 21T series cell lines (DOI: 10.1186/s13058-019-1173-5).
U-HO1-PTPN1 was derived from U-HO1 by stable transfection with non-receptor protein-tyrosine phosphatase N1 (PTPN1) (DOI: 10.1186/1471-2121-11-99).
SKG-IIB was established from the same individual as SKG-II (https://ci.nii.ac.jp/naid/110002117678/en).;The SKG-II-LUC and SKG-II-S cell lines were derived from SKG-II by transfection with LUC or TS-expressing vectors respectively (DOI: 10.1159/000063804). ;SKG-II-SF was established from SKG-II by growth in serum-free media (PMID: 9573483). ;The HKMUS cell line has been shown to be a SKG-II-SF derivative (PMID: 20143388).
SKG-IIB was established from the same individual as SKG-II (https://ci.nii.ac.jp/naid/110002117678/en).;The SKG-II-LUC and SKG-II-S cell lines were derived from SKG-II by transfection with LUC or TS-expressing vectors respectively (DOI: 10.1159/000063804). ;SKG-II-SF was established from SKG-II by growth in serum-free media (PMID: 9573483). ;The HKMUS cell line has been shown to be a SKG-II-SF derivative (PMID: 20143388).
RCC4-emptyvector and RCC4-VHL were derived from the RCC4 cell line by stable transfection with pcDNA3 and pCDNA3-VHL respectively (ECACC). ;SLR24 was shown to be a RCC4 derivative (ICLAC).
RMZ-RC2 and RMZ-RC5 are clonal cell lines derived from RMZ (DOI: 10.1038/bjc.1986.273).
UT-7-EPO is an erythropoietin-dependent subline of UT-7 (DOI: 10.1182/blood.V82.2.456.456). ;UT-7-GM is a subline of UT-7 and is a bipotential cell line that can be induced to differentiate into erythroid and megakaryocytic lineages by EPO and TPO (DOI: 10.1182/blood.V89.11.4021). ;UT-7-TPO is a thrombopoietin-dependent subline of UT-7-GM (DOI: 10.1182/blood.V87.11.4552.bloodjournal87114552).
UT-7-EPO is an erythropoietin-dependent subline of UT-7 (DOI: 10.1182/blood.V82.2.456.456). ;UT-7-GM is a subline of UT-7 and is a bipotential cell line that can be induced to differentiate into erythroid and megakaryocytic lineages by EPO and TPO (DOI: 10.1182/blood.V89.11.4021). ;UT-7-TPO is a thrombopoietin-dependent subline of UT-7-GM (DOI: 10.1182/blood.V87.11.4552.bloodjournal87114552).
KCI-MOH1 is a derivative of HPAC (ICLAC).
A375_CJ1, A375_CJ2  and A375_CJ3 are drug resistant subclones of A375.
A375_CJ1, A375_CJ2  and A375_CJ3 are drug resistant subclones of A375.
HeLaSF is a variant of Hela grown in serum free conditions. HEp-2 was originally thought to be derived from an epidermoid carcinoma of the larynx, but was found to contain HeLa marker chromosomes. DNA fingerprinting has confirmed it to have been established via HeLa cell contamination (ATCC).;BCG-823 was originally reported as a human gastric adenocarcinoma cell line. However, the STR DNA analysis pattern of BCG-823 showed contamination with the HeLa cell line (PMID: 26116706; 28851942).;GLC-82 was originally reported as a human lung adenocarcinoma cell line from a 32-year-old female patient. However, the STR DNA analysis pattern of GLC-82 showed contamination with the HeLa (PMID: 26116706).
U-118-MG and U-138-MG have identical VNTR, similar STR patterns and are very similar cytogenetically sharing at least six derivative marker chromosomes. (ATCC). ;1321N1 is a subclone of 1181N1 which itself is a subclone of U-118 MG  (ECACC).
The hTERT-immortalized foreskin fibroblast cell line, BJ-5ta, was derived by transfecting the BJ foreskin fibroblast cell line with the pGRN145 hTERT-expressing plasmid (ATCC).
A375_CJ1, A375_CJ2  and A375_CJ3 are drug resistant subclones of A375.
HeLaSF is a variant of Hela grown in serum free conditions. HEp-2 was originally thought to be derived from an epidermoid carcinoma of the larynx, but was found to contain HeLa marker chromosomes. DNA fingerprinting has confirmed it to have been established via HeLa cell contamination (ATCC).;BCG-823 was originally reported as a human gastric adenocarcinoma cell line. However, the STR DNA analysis pattern of BCG-823 showed contamination with the HeLa cell line (PMID: 26116706; 28851942).;GLC-82 was originally reported as a human lung adenocarcinoma cell line from a 32-year-old female patient. However, the STR DNA analysis pattern of GLC-82 showed contamination with the HeLa (PMID: 26116706).
CMK11-5 is a subclone of CMK (PMID: 1391807).;CMK, CMK-86 and CMK-11-5 share high SNP identity (DOI: 10.1038/nature11003).
U-118-MG and U-138-MG have identical VNTR, similar STR patterns and are very similar cytogenetically sharing at least six derivative marker chromosomes. (ATCC). ;1321N1 is a subclone of 1181N1 which itself is a subclone of U-118 MG  (ECACC).
NCI-BL1339 is a lymphoblastoid line from the same patient as NCI-H1339. (PMID: 8806092).
21NT and 21PT were independent samples derived from primary tumours from the same patient.;21MT was derived from a pleural effusion sample taken 1 year after the primary tumour samples and was subsequently used to establish the cell lines 21MT-1 and 21MT-2 (PMID: 1977518). ;H16N2 was derived from normal mammary epithelial cells taken from the same patient as the 21T series cell lines (DOI: 10.1186/s13058-019-1173-5).
MZ7-B and MZ7-mel are derived from the same patient (DOI: 10.1073/pnas.0500090102).
NTERA-2 was established in 1980 from a nude mouse xenograft of the Tera 2 cell line. ;NTERA-2-cl-D1 is a sub-clone of NTERA-2 (ATCC).
RKO-E6 was generated from the colon carcinoma line RKO by transfection with pCMV E6 using Lipofectin (ATCC).
HUH-6-clone5 is a subclone of HuH-6 (PMID: 57894).
J-RT3-T3-5 is a derivative mutant of the Jurkat subclone Jurkat-Clone-E61 that lacks the beta chain of the T cell antigen receptor (ATCC).;A3 is a wild-type A3 subclone of Jurkat generated through treatment with Fas Antibody and is very sensitive to Fas-mediated apoptosis (ATCC).;I-9-2 and I-2-1 are subclones of A3 generated by treating A3 clone with ICR-191 (frameshifting mutagen) in the presence of Fas Antibody for 3-5 weeks (ATCC).;I-9-2 has a mutation in the cysteine protease caspase-8/FLICE (ATCC).;I-2-1 has amutation in the adaptor FADD (ATCC).;Jurkat-Clone-E61 is a clone of Jurkat-FHCRC which is itself a derivative of the Jurkat cell line (ATCC).;JKT-beta-del is a derivative of Jurkat isolated by cell sorting and lacks the surface expression of the T-cell receptor alpha/beta/CD3 complex. (JCRB)
BB65-EBV is a matched normal line initiated by Epstein Barr virus (EBV) transformation from the same patient as BB65-RCC.
BE-13 and PEER show identical DNA fingerprints presumably due to cross-contamination; however, their diploid and tetraploid karyotypes are indicative of earlier and later passage numbers suggesting that BE-13 is derived from PEER, rather than vice-versa (DSMZ).
RWPE-2 was derived from RWPE-1 by transformation with Ki-ras using the Kirsten murine sarcoma virus.;RWPE2-W99 cell line was derived from the RWPE-2 by cloning in soft agar to select cells that show high expression of Ki-ras (ATCC). ;WPE1-NA22 cells were derived from RWPE-1 cells by exposure to N-methyl-N-nitrosourea (ATCC).
B239 and B240 are matched normal lines initiated by Epstein Barr virus (EBV) transformation of cells from the same blood sample as the tumour line NALM-19. (PMID: 1664237)
NCI-H1819 and the matched normal line NCI-BL1819 were derived from the same patient as NCI-H1693 following chemotherapy. (PMID: 8806092)
NCI-BL2347 is a lymphoblastoid line from the same patient as NCI-H2347 (ATCC).
NCI-BL1184 is a matched normal line initiated by Epstein Barr virus (EBV) transformation from the same patient as NCI-H1184. (ATCC)
B239 and B240 are matched normal lines initiated by Epstein Barr virus (EBV) transformation of cells from the same blood sample as the tumour line NALM-19. (PMID: 1664237)
RWPE-2 was derived from RWPE-1 by transformation with Ki-ras using the Kirsten murine sarcoma virus.;RWPE2-W99 cell line was derived from the RWPE-2 by cloning in soft agar to select cells that show high expression of Ki-ras (ATCC). ;WPE1-NA22 cells were derived from RWPE-1 cells by exposure to N-methyl-N-nitrosourea (ATCC).
PG-B95-8 is a matched normal line initiated by Epstein Barr virus (EBV) transformation from the same patient as PGA-1 (DSMZ).
NCI-BL2141 is a lymphoblastoid line from the same patient as NCI-H2141 (ATCC).
BB30-PBL is a matched normal line initiated by Epstein Barr virus (EBV) transformation from the same patient as BB30-HNC.
C3A is clonal derivative of Hep-G2 that was selected for strong contact inhibition of growth, high albumin production, high production of alpha fetoprotein (AFP) and ability to grow in glucose deficient medium (ATCC).
CGTH-W-1 is a subclone of SW-579 established in 1995 (PMID: 25877200).
HA7-EBV is a matched normal line initiated by Epstein Barr virus (EBV) transformation from the same patient as HA7-RCC.
HCC1143-BL is a B-lymphoblastoid cell line initiated using peripheral blood lymphocytes obtained from the same patient as HCC1143 (ATCC).
HCC1937-BL is a B-lymphoblastoid cell line initiated by Epstein Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from the same patient as HCC1937 (ATCC).
HCC2157-BL is a B-lymphoblastoid cell line initiated by Epstein Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from the same patient as HCC2157 (ATCC).
HCC2218-BL is a B-lymphoblastoid cell line initiated by Epstein Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from the same patient as HCC2218 (ATCC).
HCC38-BL is a B-lymphoblastoid cell line initiated by Epstein Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from the same patient as HCC38 (ATCC).
IMR-5 is a subclone of IMR-32 (DOI: 10.1016/S0304-3835(02)00581-5).
L542 is a matched normal line initiated by Epstein Barr virus (EBV) transformation from the same patient as D-542MG.
LB1047-EBV is a matched normal line initiated by Epstein Barr virus (EBV) transformation from the same patient as LB1047-RCC.
LB2241-EBV is a matched normal line initiated by Epstein Barr virus (EBV) transformation from the same patient as LB2241-RCC.
LB2518-EBV is a matched normal line initiated by Epstein Barr virus (EBV) transformation from the same patient as LB2518-MEL.
LB373-EBV is a matched normal line initiated by Epstein Barr virus (EBV) transformation from the same patient as LB373-MEL, the parental line of LB373-MEL-D.
LB831-EBV is a matched normal line initiated by Epstein Barr virus (EBV) transformation from the same patient as LB831-BLC.
LS1034-PBL is a matched normal line initiated by Epstein Barr virus (EBV) transformation from the same patient as LS1034.
NCI-BL209 is a lymphoblastoid line from the same patient as NCI-H209 (ATCC).
NCI-BL2171 is a lymphoblastoid line from the same patient as NCI-H2171 (ATCC).
Ramos-2G6-4C10 was derived from the Ramos cell line by repetitive cloning with selection for low constitutive expression of CD23 and maximum stimulation of CD23 expression by IL4 (ATCC).
TUR (TPA U937 Resistant) is a stably transfected cell line generated by Ralf Hass and Masanori Hirano in 1992 from U-937 (ATCC).
YMB-1 and YMB-1-E have been shown to be derivatives of ZR-75-1 (JCRB, ICLAC, PMID: 23136038).
The C2BBe1 (brush border expressing) cell line was cloned in 1988 from the Caco 2 cell line (ATCC).
TIG-3 and TIG-3S were established from fetal lung and skin samples respectively from the same individual (DOI: 10.34425/zs000693).;TIG-3TD is a TERT-immortalised cell line of TIG-3 (Cellosaurus).
CP50-EBV is a matched normal line initiated by Epstein Barr virus (EBV) transformation from the same patient as CP50-MEL-B.
ST is a subclone of Tanoue.;GR-ST is a subclone of ST cells transformed with human G-CSF receptor cDNA (JCRB).
The H9 cell line is a clonal derivative of the Hut 78 cell line (ATCC & PMID: 2567177).
HCC1187-BL is a B-lymphoblastoid cell line initiated by Epstein Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from the same patient as HCC1187 (ATCC).
HCC1395-BL is a B-lymphoblastoid cell line initiated by Epstein Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from the same patient as the breast carcinoma cell line HCC1395 (ATCC).
HCC1599-BL is a B-lymphoblastoid cell line initiated by Epstein Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from the same patient as HCC1599 (ATCC).
LB647-PBL is a matched normal line initiated by Epstein Barr virus (EBV) transformation from the same patient as LB647-SCLC.
LB996-EBV is a matched normal line initiated by Epstein Barr virus (EBV) transformation from the same patient as LB996-RCC.
LU-99A is a subclone of LU-99.
MC-CAR-Z2 is a derivative of MC-CAR (ATCC).
MC-IXC is a twice cloned subline of the neuroepithelioma cell line SK-N-MC (ATCC).
MMAc-SF is a serum-free medium adapted version of the MMAc cell line (RIKEN).
NCI-BL128 is a matched normal line initiated by Epstein Barr virus (EBV) transformation from the same patient as NCI-H128. (ATCC)
NCI-BL1437 is a matched normal line initiated by Epstein Barr virus (EBV) transformation from the same patient as NCI-H1437. (ATCC)
NCI-BL2009 is a lymphoblastoid line derived from the same patient as NCI-H2009 (ATCC).
NCI-BL2052 is a lymphoblastoid line derived from the same patient as NCI-H2052 (ATCC).
NCI-BL2087 is a lymphoblastoid line from the same patient as NCI-H2087 (ATCC).
NCI-BL2126 is a B-lymphoblastoid cell line initiated by Epstein Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from the same patient as NCI-H2126 (ATCC).
MC-IXC is a twice cloned subline of the neuroepithelioma cell line SK-N-MC (ATCC).
Panc-10-05 was derived from the same patient as the PL45 cell line (ATCC).
HuG1-N and HuG1-PI were derived from the parental line HuG1 (JCRB).
NCI-BL1184 is a matched normal line initiated by Epstein Barr virus (EBV) transformation from the same patient as NCI-H1184. (ATCC)
J82-EBV was derived from the same patient as J82.
KPL-1 has been shown by DNA fingerprinting to be cross-contaminated with cell line MCF-7 (DSMZ).
MM1R is a dexamethasone resistant line derived from MM1. ;MM1S is a dexamethasone sensitive line derived from MM1 (ATCC).
TE-2, TE-3, TE-7, TE-12 & TE-13 share common ancestry (PMID: 17804709)
TE-2, TE-3, TE-7, TE-12 & TE-13 share common ancestry (PMID: 17804709)
NCI-ADR-RES has been shown to be derivitive of OVCAR-8 (ICLAC)
NCI-H125 and NCI-H513 have been show to be cross contaminated (ATCC, ICLAC)
B2-17 has been shown to be a derivitive of U251.;SNB19 has been shown to be a derivitive of U251 (ICLAC).
B2-17 has been shown to be a derivitive of U251.;SNB19 has been shown to be a derivitive of U251 (ICLAC).
COLO-320 and COLO-320-HSR share common ancestry.
Malme-3M is a tumour line isolated from the same patient as Malme-3, a normal skin fibroblast (ATCC).
NCI-BL2052 is a lymphoblastoid line derived from the same patient as NCI-H2052 (ATCC).
P3HR-1 is a clonally derived subline of Jiyoye.;2B8 is a HAT sensitive fusion cell line derived from the P3HR-1 (ATCC).
J-RT3-T3-5 is a derivative mutant of the Jurkat subclone Jurkat-Clone-E61 that lacks the beta chain of the T cell antigen receptor (ATCC).;A3 is a wild-type A3 subclone of Jurkat generated through treatment with Fas Antibody and is very sensitive to Fas-mediated apoptosis (ATCC).;I-9-2 and I-2-1 are subclones of A3 generated by treating A3 clone with ICR-191 (frameshifting mutagen) in the presence of Fas Antibody for 3-5 weeks (ATCC).;I-9-2 has a mutation in the cysteine protease caspase-8/FLICE (ATCC).;I-2-1 has amutation in the adaptor FADD (ATCC).;Jurkat-Clone-E61 is a clone of Jurkat-FHCRC which is itself a derivative of the Jurkat cell line (ATCC).;JKT-beta-del is a derivative of Jurkat isolated by cell sorting and lacks the surface expression of the T-cell receptor alpha/beta/CD3 complex. (JCRB)
MDA-MB-435 and its variant MDA-MB435S have been found to be cross contaminated with M14 (ICLAC, DOI: 10.1002/ijc.31067)
MOLM-13 and MOLM-14 are sister cell lines, both established from the peripheral blood of the same patient (DSMZ).
MONO-MAC-1 and MONO-MAC-6 are simultaneous sister cell lines derived from a peripheral blood sample from the same patient (DSMZ).
NCI-H1993 and NCI-H2073 were derived from the same patient (ATCC).
NCI-BL2122 is a lymphoblastoid line from the same patient as NCI-H2122 (ATCC).
OC-314, OC-315 and OC-316 share common ancestry (PMID: 15677628). Sanger and Broad Institute genomic data supports this conclusion for OC-314 & OC-316 (no data has been generated for OC-315).
RH-41 and RH-4 were both derived from the same patient sample. (PMID: 23882450)
WIL2-S is a HAT sensitive variant of the WIL2-NS cell line (ATCC).
M120326_2 and M120327_3 were established from two different samples obtained from different regions of the same tumour.
TE-2, TE-3, TE-7, TE-12 & TE-13 share common ancestry (PMID: 17804709)
HCM-SANG-0311-C15-B was derived from a sample obtained prior to the patient receiving chemotherapy.;HCM-SANG-0311-C15 is derived from a sample collected following chemotherapy (Capecitabine & Dexamethasone).
HCM-SANG-0311-C15-B was derived from a sample obtained prior to the patient receiving chemotherapy.;HCM-SANG-0311-C15 is derived from a sample collected following chemotherapy (Capecitabine & Dexamethasone).
MOLM-13 and MOLM-14 are sister cell lines, both established from the peripheral blood of the same patient (DSMZ).
Ishikawa and Ishikawa(Heraklio)02ER- were derived from the same patient.
LN-464 and ACN share common ancestry (Sanger & Broad).
NCI-BL1395 is a lymphoblastoid line established from the same patient as NCI-H1395 (ATCC).
The human umbilical vein cell line, EA.hy926, was established by fusing primary human umbilical vein cells with a thioguanine-resistant clone of A549 by exposure to polyethylene glycol (PEG). Hybrid clones were selected in HAT medium and screened for factor VIII-related antigen. (ATCC)
DLD-1, HCT-15, HCT-8 and HRT-18 have been shown to have a common genetic origin (ECACC & PMID: 9809040).
HCMB and RPMI-7932 were both derived from the same patient (ATCC).;CHL-1 is a dervivative of RPMI-7932 (ATCC).;;COLO-699N (COLO-699) and COLO-738 were found to be indistinguishable from RPMI-7932 by STR profiling. All three cell lines were received from the same depositor (ECACC).
HCMB and RPMI-7932 were both derived from the same patient (ATCC).;CHL-1 is a dervivative of RPMI-7932 (ATCC).;;COLO-699N (COLO-699) and COLO-738 were found to be indistinguishable from RPMI-7932 by STR profiling. All three cell lines were received from the same depositor (ECACC).
A375_CJ1, A375_CJ2  and A375_CJ3 are drug resistant subclones of A375.
HeLaSF is a variant of Hela grown in serum free conditions. HEp-2 was originally thought to be derived from an epidermoid carcinoma of the larynx, but was found to contain HeLa marker chromosomes. DNA fingerprinting has confirmed it to have been established via HeLa cell contamination (ATCC).;BCG-823 was originally reported as a human gastric adenocarcinoma cell line. However, the STR DNA analysis pattern of BCG-823 showed contamination with the HeLa cell line (PMID: 26116706; 28851942).;GLC-82 was originally reported as a human lung adenocarcinoma cell line from a 32-year-old female patient. However, the STR DNA analysis pattern of GLC-82 showed contamination with the HeLa (PMID: 26116706).
HP is a polytropic retroviral packaging cell line derived from the human fibrosarcoma cell line, HT-1080 (ATCC).;HX is a xenotropic retroviral packaging cell line derived from the human fibrosarcoma cell line, HT-1080 (ATCC).;PEAZ-1 has been shown to be contaminated wih HT-1080 (ICLAC).;
EFM-192B and EFM-192C were established from the same patient as EFM-192A (DSMZ).
SH-SY5Y is a thrice cloned (SK-N-SH -> SH-SY -> SH-SY5 -> SH-SY5Y) subline of the neuroblastoma cell line SK-N-SH (ATCC).
A2780cis is a cisplatin resistant subclone of A2780.;A2780ADR is an adriamycin resistant subclone of A2780 (ECACC).
YSCCC-G10 and YSCCC-G100 are gemcitabine‐resistant cells generated by exposing the YSCCC cell line to 10nM and 100nM of gemcitabine respectively (DOI: 10.1007/s00534-011-0376-7).
BB49-EBV is a matched normal line initiated by Epstein Barr virus (EBV) transformation from the same patient as BB49-HNC.
NCI-BL1770 is a lymphoblastoid line established from the same patient as NCI-H1770 (ATCC).
HOUA-II is a lymphoblastoid line from the same patient as HOUA-I. (Cellosaurus: CLPUB00051).
HOUA-II is a lymphoblastoid line from the same patient as HOUA-I. (Cellosaurus: CLPUB00051).
HOTHC-SF is a serum and protein free culture derivative of HOTHC (JCRB).
HOTHC-SF is a serum and protein free culture derivative of HOTHC (JCRB).
P2UR_K-562 is a P2U receptor-expressing subline derived from K-562 (RIKEN).
HAP1 is a subclone of KBM7 which is haploid except for a disomy of chromosome 8; 25, XY, +8, Ph+ (10.1242/bio.057174).
HAP1 is a subclone of KBM7 which is haploid except for a disomy of chromosome 8; 25, XY, +8, Ph+ (10.1242/bio.057174).
RCC4-emptyvector and RCC4-VHL were derived from the RCC4 cell line by stable transfection with pcDNA3 and pCDNA3-VHL respectively (ECACC). ;SLR24 was shown to be a RCC4 derivative (ICLAC).